Value
5.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 5.0 |
AKTS · Why this verdict
Why Aktis Oncology (AKTS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Aktis Oncology is growing revenue at 123% year-over-year with favorable analyst sentiment and 37% upside to the consensus target — but quality metrics fall below the minimum threshold for entry, earnings have missed three of the past four quarters, and a 17% short interest adds downside risk if clinical momentum stalls.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business scores below the minimum quality floor, with absent gross margin and net margin data, a Piotroski F-Score of 4.4, and confirmed quality concerns — making the quality shortfall the single largest hurdle to entry regardless of near-term price action. Warnings | Gross margin turning positive and sustaining above 30% for two consecutive quarters would demonstrate that the business model is generating unit economics sufficient to clear the quality bar. | →Stable |
| CounterEarly-stage oncology companies routinely operate with pre-commercialization cost structures; if the pipeline matures toward product revenue, quality metrics could inflect rapidly and the quality shortfall may prove temporary. | ||
Revenue is expanding at 123% year-over-year, placing the company at the top of its peer group for growth — a pace that, if sustained, could rapidly change the business's quality and valuation profile. Growth breakdown | Revenue growth sustaining above 50% for the next two reporting periods would confirm the trajectory is not reverting to a one-period event. | →Stable |
| CounterBiotech revenue can be lumpy and milestone-driven; a single large contract recognition or licensing event can inflate the growth rate artificially, making comparisons in subsequent quarters look weak. | ||
Three of the past four quarters produced earnings misses, including one that came in 435% below consensus — a pattern suggesting the cost trajectory or revenue ramp is consistently harder to predict than management or analysts project. Earnings | EPS surprise turning positive for two consecutive quarters would signal improved guidance calibration or cost control. | →Stable |
| CounterThe single beat quarter delivered a 54% positive surprise, indicating that when the company does execute, it can do so decisively; the outsized miss may reflect a one-time estimate calibration error rather than chronic underperformance. | ||
At 37.3% headroom to the consensus price target with a reward-to-risk ratio of 5.3-to-1, the asymmetry is structurally attractive — but this upside can only be realized if the quality shortfall is addressed and clinical or commercial milestones are delivered. Price targets | Price approaching within 10% of the $28.41 analyst target over 12 months while the company demonstrates measurable improvement in gross margin. | →Stable |
| CounterAnalyst targets for early-stage biotechs are often driven by pipeline assumptions rather than earnings power, making them subject to abrupt downward revision on adverse trial or enrollment data. | ||
The business scores below the minimum quality floor, with absent gross margin and net margin data, a Piotroski F-Score of 4.4, and confirmed quality concerns — making the quality shortfall the single largest hurdle to entry regardless of near-term price action.
→StableWarnings
- Expectation
- Gross margin turning positive and sustaining above 30% for two consecutive quarters would demonstrate that the business model is generating unit economics sufficient to clear the quality bar.
CounterEarly-stage oncology companies routinely operate with pre-commercialization cost structures; if the pipeline matures toward product revenue, quality metrics could inflect rapidly and the quality shortfall may prove temporary.
Revenue is expanding at 123% year-over-year, placing the company at the top of its peer group for growth — a pace that, if sustained, could rapidly change the business's quality and valuation profile.
→StableGrowth breakdown
- Expectation
- Revenue growth sustaining above 50% for the next two reporting periods would confirm the trajectory is not reverting to a one-period event.
CounterBiotech revenue can be lumpy and milestone-driven; a single large contract recognition or licensing event can inflate the growth rate artificially, making comparisons in subsequent quarters look weak.
Three of the past four quarters produced earnings misses, including one that came in 435% below consensus — a pattern suggesting the cost trajectory or revenue ramp is consistently harder to predict than management or analysts project.
→StableEarnings
- Expectation
- EPS surprise turning positive for two consecutive quarters would signal improved guidance calibration or cost control.
CounterThe single beat quarter delivered a 54% positive surprise, indicating that when the company does execute, it can do so decisively; the outsized miss may reflect a one-time estimate calibration error rather than chronic underperformance.
At 37.3% headroom to the consensus price target with a reward-to-risk ratio of 5.3-to-1, the asymmetry is structurally attractive — but this upside can only be realized if the quality shortfall is addressed and clinical or commercial milestones are delivered.
→StablePrice targets
- Expectation
- Price approaching within 10% of the $28.41 analyst target over 12 months while the company demonstrates measurable improvement in gross margin.
CounterAnalyst targets for early-stage biotechs are often driven by pipeline assumptions rather than earnings power, making them subject to abrupt downward revision on adverse trial or enrollment data.
Per-dimension breakdown
Quality
2.9/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.0 |
| Piotroski F | 4.4 |
- ▸No competitive moat
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 123% YoY
Momentum
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 6.7 |
- ▸Overbought bear rally (RSI 82)
- ▸Volume accumulation (rising OBV)
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.6 |
| Price target | 7.5 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (6.0) — signal dampened
Insider
5.1/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.2 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 8.7 |
- ▸Industry growth leader
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.2 |
| 52w position | 9.7 |
Risk (lower is worse)
1.1/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 1.6 |
| days to cover | 0.0 |
| volatility | 0.0 |
| debt equity | 2.7 |
- ▸High short interest: 17%
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.3>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:50d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.2<1.5@spot
Warning (0)
none
Reward-to-Risk
0.18
Upside
+2.7%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.5B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.2<1.5@spot.
The strongest dimensions are Growth at 10.0, Momentum at 7.3, and Sentiment at 6.8; the weakest are Risk (lower is worse) at 1.1, Catalyst at 2.5, and Quality at 2.9. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 0.18 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The business scores below the minimum quality floor, with absent gross margin and net margin data, a Piotroski F-Score of 4.4, and confirmed quality concerns — making the quality shortfall the single largest hurdle to entry regardless of near-term price action.
Trip ifGross margin turns positive and sustains above 30% for 2 consecutive quarters.
- P2Revenue is expanding at 123% year-over-year, placing the company at the top of its peer group for growth — a pace that, if sustained, could rapidly change the business's quality and valuation profile.
Trip ifRevenue growth falls below 20% YoY for 2 consecutive quarters.
- P3Three of the past four quarters produced earnings misses, including one that came in 435% below consensus — a pattern suggesting the cost trajectory or revenue ramp is consistently harder to predict than management or analysts project.
Trip ifEPS surprise exceeds 0% for 2 consecutive quarters.
- P4At 37.3% headroom to the consensus price target with a reward-to-risk ratio of 5.3-to-1, the asymmetry is structurally attractive — but this upside can only be realized if the quality shortfall is addressed and clinical or commercial milestones are delivered.
Trip ifAnalyst consensus price target falls below $23, compressing upside to less than 15% from current levels.